US-funded Hepatitis B Vaccine Study in Guinea-Bissau Canceled Amid Controversy Over Ethical Concerns.
A US-funded study on administering hepatitis B vaccines to newborns in Guinea-Bissau has been canceled due to concerns over its ethics, according to a senior official at the Africa Centres for Disease Control and Prevention (CDC). The $1.6 million study had drawn widespread criticism after raising questions about withholding life-saving vaccines from children.
Guinea-Bissau's officials said the trial would proceed but only if redesigned to address ethical issues raised by critics. The CDC's Boum stated that "the way the study was designed" posed significant challenges and led to its cancellation.
Critics have long argued that giving 7,000 newborns a life-saving vaccine while withholding it from another group is morally reprehensible. Paul Offit, an infectious diseases physician at the Children's Hospital of Philadelphia, welcomed the news, saying, "This administration did not see people in Africa as valuable." He likened the study to the infamous Tuskegee experiment, where African American men were denied effective treatment for syphilis.
The cancellation comes amidst a growing movement to push back against what critics say is unethical and exploitative research in Africa. Boghuma Titanji, an assistant professor of medicine at Emory University, said that the halt was "a win for advocacy and upholding the ethics of research." However, she noted that such studies can have long-lasting damage if they proceed as planned.
The study's design had been criticized for prioritizing a trial on vaccine efficacy over its potential impact on public health. Critics argue that trials should be led by African scientists and powered by questions from Africans, rather than being conducted by outsiders with questionable motives.
The cancellation of the study has sparked hope that Guinea-Bissau and other countries can move away from what critics say is exploitative research practices.
A US-funded study on administering hepatitis B vaccines to newborns in Guinea-Bissau has been canceled due to concerns over its ethics, according to a senior official at the Africa Centres for Disease Control and Prevention (CDC). The $1.6 million study had drawn widespread criticism after raising questions about withholding life-saving vaccines from children.
Guinea-Bissau's officials said the trial would proceed but only if redesigned to address ethical issues raised by critics. The CDC's Boum stated that "the way the study was designed" posed significant challenges and led to its cancellation.
Critics have long argued that giving 7,000 newborns a life-saving vaccine while withholding it from another group is morally reprehensible. Paul Offit, an infectious diseases physician at the Children's Hospital of Philadelphia, welcomed the news, saying, "This administration did not see people in Africa as valuable." He likened the study to the infamous Tuskegee experiment, where African American men were denied effective treatment for syphilis.
The cancellation comes amidst a growing movement to push back against what critics say is unethical and exploitative research in Africa. Boghuma Titanji, an assistant professor of medicine at Emory University, said that the halt was "a win for advocacy and upholding the ethics of research." However, she noted that such studies can have long-lasting damage if they proceed as planned.
The study's design had been criticized for prioritizing a trial on vaccine efficacy over its potential impact on public health. Critics argue that trials should be led by African scientists and powered by questions from Africans, rather than being conducted by outsiders with questionable motives.
The cancellation of the study has sparked hope that Guinea-Bissau and other countries can move away from what critics say is exploitative research practices.